NewLink Genetics Corp (NASDAQ:NLNK)

42.06
Delayed Data
As of May 22
 +0.10 / +0.24%
Today’s Change
17.32
Today|||52-Week Range
58.73
+5.81%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.2B

Company Description

NewLink Genetics Corp. is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.

Contact Information

NewLink Genetics Corp.
2503 South Loop Drive
Ames Iowa 50010
P:(515) 296-5555
Investor Relations:

Employees

Shareholders

Individual stakeholders28.26%
Other institutional27.27%
Mutual fund holders23.76%

Top Executives

Charles J. LinkChairman, Chief Executive & Scientific Officer
Nicholas N. VahanianPresident & Chief Medical Officer
John B. HennemanChief Financial Officer, Secretary & Executive VP
W. Jay RamseyChief Clinical & Compliance Officer
Brian WileyVice President-Business Development

To view my watchlist

Not a member yet?

Sign up now for a free account